Navigation Links
Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
Date:9/28/2007

of the results from NAI's acquisition of Real Health Laboratories, Inc. for a full year in fiscal 2007 as compared to a partial year in fiscal 2006. The decrease in selling, general and administrative expenses for the fourth quarter of fiscal 2007 from the comparable quarter in the prior year was primarily due to reduced personnel expenses from the termination of certain sales and marketing personnel in June 2006. Additionally, NAI believes it will be required to recognize a non-cash, material goodwill impairment charge, which will have a negative effect on its results of operations but will not impact its cash flows or cash position. As NAI has not yet completed its annual goodwill impairment testing, it is unable to provide a reasonable estimate of the amount of such charge at this time.

President Randell Weaver said, "Revenue for the fourth quarter of fiscal 2007 was slightly higher than third quarter revenue though it was down compared to the year ago quarter because the fourth quarter of fiscal 2006 included significant initial shipments of a single product for a new customer. Revenue in the first quarter of fiscal 2008 is expected to exceed revenue in the fourth quarter of fiscal 2007 and is expected to be in line with revenue in the first quarter of fiscal 2007. We expect to report working capital of $16.1 million at June 30, 2007 compared to $13.2 million at June 30, 2006. We also expect to report cash at June 30, 2007 of $4.9 million. As of June 30, 2007, there were no outstanding borrowings under our working capital line of credit. We expect to finalize our annual goodwill impairment testing no later than October 15, 2007 and issue a release of our final corporate earnings at that time."

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nu
'/>"/>

SOURCE Natural Alternatives International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Unnatural death common in mentally ill
2. Eczema patients lack natural antibiotic in skin
3. Accuracy of Some Natural Family Planning Methods Questioned .
4. Natural formula for protection against vision loss
5. Naturally Occurring Hormone Can Lead To Miscarriage
6. Treating Leukemia With Natural Cells
7. The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties
8. Natural Sulfur Can Treat Pain From Osteoarthritis
9. Chronic Post-Traumatic Stress Disorder (PTSD) Risk In Young Natural Disaster Survivors
10. Tsunami Unplugged: Natural Disasters Favor the Under-privileged
11. Studies Advocate Natural Form Of Vitamin E
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 2Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 3Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 4Health News:Veterans Organizations Call For Early Lung Cancer Detection Research 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 3Health News:HLTH Corporation Announces Fourth Quarter Financial Results 4Health News:HLTH Corporation Announces Fourth Quarter Financial Results 5Health News:HLTH Corporation Announces Fourth Quarter Financial Results 6Health News:HLTH Corporation Announces Fourth Quarter Financial Results 7Health News:HLTH Corporation Announces Fourth Quarter Financial Results 8Health News:HLTH Corporation Announces Fourth Quarter Financial Results 9Health News:HLTH Corporation Announces Fourth Quarter Financial Results 10Health News:HLTH Corporation Announces Fourth Quarter Financial Results 11Health News:HLTH Corporation Announces Fourth Quarter Financial Results 12Health News:HLTH Corporation Announces Fourth Quarter Financial Results 13Health News:HLTH Corporation Announces Fourth Quarter Financial Results 14Health News:HLTH Corporation Announces Fourth Quarter Financial Results 15Health News:HLTH Corporation Announces Fourth Quarter Financial Results 16Health News:HLTH Corporation Announces Fourth Quarter Financial Results 17Health News:HLTH Corporation Announces Fourth Quarter Financial Results 18Health News:HLTH Corporation Announces Fourth Quarter Financial Results 19Health News:HLTH Corporation Announces Fourth Quarter Financial Results 20Health News:HLTH Corporation Announces Fourth Quarter Financial Results 21Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 2Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 3Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 4
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 618th Annual Texas Autism Conference Returns To Corpus Christi Makes Nearly 24300 000 Economic Impact 62267 118th Annual Texas Autism Conference Returns To Corpus Christi Makes Nearly 24300 000 Economic Impact 62267 2OmniActive and Kemin Reach Amicable Settlement in Patent Dispute 62262 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 2